Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.20.2
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2020
Jun. 30, 2020
Current assets:    
Cash and cash equivalents $ 77,543,000 $ 55,112,000
Accounts receivable - trade 300,000 75,000
Subscription receivable 0 5,549,000
Investments in debt securities 6,010,000 0
Work in process 843,000 798,000
Prepaid expenses and other current assets 263,000 214,000
Total Current Assets 84,959,000 61,748,000
Finance lease right-of-use assets, net of accumulated amortization 27,201,000 27,616,000
Fixed assets, net of accumulated depreciation 3,834,000 3,657,000
Intangible assets, net of accumulated amortization 1,236,000 1,144,000
Security deposits 24,000 24,000
Total Assets 117,254,000 94,189,000
Current liabilities:    
Accounts payable (related parties of $124 and $6 as of September 30, 2020 and June 30, 2020, respectively) 1,602,000 1,759,000
Accrued expenses (related party of $847 and $705 as of September 30, 2020 and June 30, 2020, respectively) 1,406,000 1,105,000
Note payable - PPP Loan - current portion 362,000 261,000
Finance lease obligation - current portion 306,000 301,000
Contract liabilities 1,370,000 1,810,000
Total Current Liabilities 5,046,000 5,236,000
Note payable - PPP Loan - net of current portion 238,000 339,000
Finance lease obligation - net of current portion 31,928,000 32,007,000
Total Liabilities 37,212,000 37,582,000
Commitments and Contingencies
iBio, Inc. Stockholders' Equity:    
Common stock - $0.001 par value; 275,000,000 shares authorized; 180,317,751 and 140,071,110 shares issued and outstanding as of September 30, 2020 and June 30, 2020, respectively 180,000 140,000
Additional paid-in capital 237,867,000 206,931,000
Accumulated other comprehensive loss (40,000) (33,000)
Accumulated deficit (157,953,000) (150,420,000)
Total iBio, Inc. Stockholders' Equity 80,054,000 56,618,000
Noncontrolling interest (12,000) (11,000)
Total Equity 80,042,000 56,607,000
Total Liabilities and Equity 117,254,000 94,189,000
iBio CMO    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued 0 0
Series B Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued $ 0 $ 0